Navigation Links
Multidisciplinary Association for Psychedelic Studies (MAPS) Selects Montrium's eTMF Platform as They Begin Phase 3 Studies of MDMA-assisted Psychotherapy for PTSD
Date:9/18/2017

MONTREAL, Sept. 18, 2017 /PRNewswire/ -- Montrium, a growing leader in Electronic Trial Master file solutions, today announced an exciting new partnership with a groundbreaking non-profit research organization, Multidisciplinary Association for Psychedelic Studies (MAPS).

MAPS Public Benefit Corporation selects eTMF Connect for MDMA-assisted psychotherapy studies for PTSD
MAPS Public Benefit Corporation selects eTMF Connect for MDMA-assisted psychotherapy studies for PTSD

The FDA has recently granted Breakthrough Therapy Designation to MDMA for the treatment of Posttraumatic Stress Disorder (PTSD). MAPS also reached agreement with the FDA on the design of two Phase 3 clinical trials for MDMA-assisted psychotherapy in patients with severe PTSD through a Special Protocol Assessment (SPA). MAPS has selected Montrium's Electronic Trial Master File solution (eTMF), eTMF Connect, to support these upcoming Phase 3 studies and subsequent clinical trials.

"With such positive results during our Phase 2 trials we were confident that we would receive approval by the FDA to initiate Phase 3 studies on a larger patient population," said Amy Emerson, Director of Clinical Research and Executive Director at MPBC Public Benefit Corporation. "We realized very early on that to scale our Phase 2 successes in the next step of our journey, bringing in the appropriate technology to support this activity would be key. By partnering with Montrium, we not only leverage a sophisticated and robust eTMF system, but a knowledgeable and dedicated partner in the clinical trial arena."

Montrium's eTMF Connect solution will help MAPS improve the efficiency of trial processes by managing documents, data, and clinical activities on a single cloud platform. Researchers and Clinical teams will now be able to access clinical documents and information in real-time significantly improving collaboration and transparency. In addition, MAPS also strengthens the partnership further by joining Montrium's Customer Advisory Program to actively participate in the shaping Montrium's product development roadmap.

"As a small team paving the way in MDMA-assisted psychotherapy, MAPS faces several key challenges as they begin to scale their successes in clinical treatments," said Paul Fenton, President & CEO of Montrium. "We are extremely excited to have been selected to help support the great work the MAPS team is doing as they overcome these challenges and ensure the valuable research they are conducting reaches those in need."

About eTMF Connect

Montrium's proven eTMF Connect solution helps life sciences companies better manage their clinical trial documentation. It has been designed using the TMF Reference Model, and centralizes and standardizes your clinical records enabling both sponsors and CRO's to contribute and access important clinical documents and information in real-time. You can learn more about eTMF Connect by visiting www.montrium.com/etmf-connect

About Montrium:

Montrium is a global leader in cloud-based document & quality management solutions and GxP consulting services for the Life Sciences. Operating in the Life Sciences for over 10 years, Montrium has been successfully helping organizations implement and maintain technology to improve their business processes and increase compliance. Montrium currently serves over 8000 users in more than 20 countries. For more information on the products and services Montrium provides, please visit: www.montrium.com.

About MPBC and MAPS:

Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Since its founding, MAPS has raised over $43.7 million for psychedelic therapy and medical marijuana research and education. For more information, visit MAPS.org.

MAPS-sponsored clinical trials are conducted by the MPBC Public Benefit Corporation (MPBC), a wholly owned subsidiary of MAPS formed in 2015 for the special purpose of balancing social benefits with income from legal sales of MDMA, other psychedelics, and marijuana. For more information, visit MPBCbcorp.com

Media contact:
Oliver Pearce
176260@email4pr.com 
514 223 9153

View original content with multimedia:http://www.prnewswire.com/news-releases/multidisciplinary-association-for-psychedelic-studies-maps-selects-montriums-etmf-platform-as-they-begin-phase-3-studies-of-mdma-assisted-psychotherapy-for-ptsd-300520450.html


'/>"/>
SOURCE Montrium
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. CD-adapco's STAR Academy Accelerates Multidisciplinary Simulation Learning Curve
2. Third Annual Healthcare Leadership Forum Expands to Include Multidisciplinary Evidence-Based Practice Across Healthcare
3. Benchworks President Melissa Johnston Named Treasurer for Healthcare Businesswomen’s Association (HBA) Mid-Atlantic Chapter
4. Inspirata to Participate in Thought Leadership for Cancer Information Sharing at the Association for Pathology Informatics Annual Summit in Pittsburgh May 22-25
5. CNSDose to Demonstrate Leading Genetic Technology for Prescribing Antidepressants at the American Psychiatric Association Annual Meeting
6. Trust Transparency Consulting Launches Ingredient Trade Association Incubator Program
7. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
8. Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
9. Nerium International Approved as Member of the Mexican Direct Selling Association A.C.
10. Pertheras Chief Bioinformatics Officer Speaking at The American Medical Informatics Association (AMIA) 2017 Joint Summits Panels
11. Cellecta, Inc. Announces Upcoming Presentations at the American Association for Cancer Research 2017 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2018)... ... ... Asymmetrex’s director, James L. Sherley, M.D., Ph.D., asks audiences questions like, “How ... the means to measure the number of drug molecules in drug development research or ... holding up progress in stem cell medicine.” , “Can you imagine taking an approved ...
(Date:9/12/2018)... ... September 11, 2018 , ... Leading regenerative ... of Feline Practitioners Conference (AAFP) later this month. The company’s CEO ... therapy for the treatment of chronic kidney disease in felines at a poster ...
(Date:9/12/2018)... (PRWEB) , ... September 12, 2018 , ... ... Bronich-Hall, a quality management professional and former Senior Director of Regulatory Affairs and ... , As Senior Director of Regulatory Affairs and Quality Systems at WellDoc, ...
(Date:9/7/2018)... ... 06, 2018 , ... The Discovery on Target (DOT) conference ... industry’s preeminent event on novel drug targets.” BellBrook Labs’ high throughput screening (HTS) ... emerging targets in a quest to find new treatments for disease. , BellBrook ...
Breaking Biology Technology:
(Date:8/23/2018)... (PRWEB) , ... August 22, 2018 , ... ... release of LimitLIS® 4.0, the latest version of its rapidly growing cloud-based laboratory ... LimitLIS® Toxicology Edition, as well as the company’s triple digit growth throughout 2018, ...
(Date:8/21/2018)... ... August 20, 2018 , ... ... are many challenges to consider. Designers must ensure what is designed can be ... will explore some best practices in flow path design with specific focus on ...
(Date:8/21/2018)... ... August 21, 2018 , ... Whether it ... Labs is dedicated to offering customers a successful experience. When browsing the ... seamless transition between products, with relevant details such as technical manuals, application notes, ...
Breaking Biology News(10 mins):